Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 8.62 B
The data is delayed by 15 minutes.
JAZZ is in the medium-term down -31% below S&P in 1 year.
Description: Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment and prevention of VOD, a potentially life-threatening complication of HSCT; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD tablets for the treatment-resistant schizophrenia, as well as Versacloz for treatment-resistant schizophrenia. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate products that is under pre-clinical research and development and is intended for the treatment of narcolepsy patients.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||60.49 M||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||6.21%||Sales Growth - Q/Q||-5.74%||P/E|
|P/E To EPS Growth||P/S||6.97||P/BV||6.6||Price/Cash Per Share|
|Price/Free Cash Flow||23.32||ROA||6.85%||ROE||16.99%||ROI||8.26%|
|Current Ratio||5||Quick Ratio||4.86||Long Term Debt/Equity||1.51||Debt Ratio||0.17|
|Gross Margin||90.71%||Operating Margin||30.68%||Net Profit Margin||17.95%||Dividend Payout Ratio|
|Cash From Financing Activities||Cash From Investing Activities||-3.26 M||Cash From Operating Activities||18.29 M||Gross Profit||281.01 M|
|Net Profit||96.56 M||Operating Profit||116.76 M||Total Assets||3.24 B||Total Current Assets||1.1 B|
|Total Current Liabilities||220.58 M||Total Debt||1.33 B||Total Liabilities||1.93 B||Total Revenue||309.3 M|
|High 52 week||183.18||Low 52 week||115.94||Last close||128.44||Last change||0.6%|
|RSI||25.6||Average true range||3.64||Beta||1.32||Volume||518.32 K|
|Simple moving average 20 days||-7.38%||Simple moving average 50 days||-4.27%||Simple moving average 200 days||-14.11%|
|Performance Week||-8.13%||Performance Month||-3.84%||Performance Quart||0.82%||Performance Half||-18.65%|
|Performance Year||-18.73%||Performance Year-to-date||3.61%||Volatility daily||1.89%||Volatility weekly||4.23%|
|Volatility monthly||8.66%||Volatility yearly||30%||Relative Volume||302.29%||Average Volume||652.73 K|
|New High||New Low|
2019-04-18 20:05:05 | Are Hedge Funds Right About Jazz Pharmaceuticals?
2019-04-16 09:30:01 | JAZZ vs. ZTS: Which Stock Is the Better Value Option?
2019-04-16 08:47:07 | Should We Be Cautious About Jazz Pharmaceuticals plc's NASDAQ:JAZZ ROE Of 16%?
2019-04-16 08:45:12 | 3 Reasons Why Jazz JAZZ Is a Great Growth Stock
2019-04-11 09:46:01 | Concert Pharma Initiates Early-Stage Schizophrenia Study
2019-04-09 10:46:50 | See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
2019-04-04 10:34:00 | Jazz Pharma, Alexion and Lundbeck to pay $122.6 million to resolve kickback allegations
2019-04-01 05:00:00 | Stocks That Would Have Made You Rich Today
2019-03-28 09:30:01 | Jazz JAZZ Down 0.4% Since Last Earnings Report: Can It Rebound?
2019-03-27 16:30:08 | Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study
2019-03-26 15:33:36 | What Should Investors Know About The Future Of Jazz Pharmaceuticals plc’s NASDAQ:JAZZ?
2019-03-26 08:22:41 | See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
2019-03-22 15:01:06 | Analysts Reduce Jazz Pharmaceuticals’ Target Price in March
2019-03-20 21:05:34 | FDA approves Jazz Pharmaceutical sleep disorder drug
2019-03-20 20:02:29 | Jazz Pharma's sleep disorder treatment gets FDA nod
2019-03-20 11:14:03 | Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision
2019-03-19 11:09:22 | FDA decision on Jazz Pharmaceuticals narcolepsy drug expected Wednesday
2019-03-12 09:56:01 | Is Jazz Pharmaceuticals JAZZ a Good Value Investor Pick?
2019-03-11 09:19:01 | The Best And Worst Stocks of the 10-Year Bull Market
2019-03-07 14:22:20 | The 10 Best and 10 Worst Stocks of This 10-Year Bull Market
2019-03-05 07:15:00 | 3 Best Biotech Bargain Stocks on the Market Right Now
2019-02-28 09:15:02 | Too Much Talking, Not Enough Action
2019-02-28 08:43:01 | Jazz Pharmaceuticals JAZZ Surges: Stock Moves 7.9% Higher
2019-02-27 07:13:12 | Jazz Pharma JAZZ Q4 Earnings & Sales Beat, Stock Up 8%
2019-02-27 03:03:18 | Edited Transcript of JAZZ earnings conference call or presentation 26-Feb-19 9:30pm GMT
2019-02-27 02:08:02 | Jazz Pharmaceuticals PLC JAZZ Q4 2018 Earnings Conference Call Transcript
2019-02-26 16:31:00 | Jazz Pharma stock jumps 9% as biotech tops Wall Street Q4 views
2019-02-26 16:05:00 | Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2018 Financial Results
2019-02-26 14:30:00 | Jazz Pharmaceuticals Plc to Host Earnings Call
2019-02-24 14:30:00 | 2 Stocks You Really Should Consider Shorting This Week
2019-02-20 15:09:08 | Mylan MYL to Report Q4 Earnings: What's in the Offing?
2019-02-15 08:10:00 | New Research: Key Drivers of Growth for IPG Photonics, Keane Group, Jazz Pharmaceuticals, Tredegar, Carriage Services, and Surgery Partners — Factors of Influence, Major Initiatives and Sustained Production
2019-02-14 16:05:00 | Jazz Pharmaceuticals Announces Appointment of Anne O'Riordan to its Board of Directors
2019-02-12 09:53:02 | Factors to Know Ahead of Herbalife's HLF Q4 Earnings
2019-02-06 10:10:03 | Why Jazz JAZZ Could Beat Earnings Estimates Again
2019-01-29 08:03:20 | See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.